This finding supports the tandem use of anti-CD38 antibodies and PD-1/PD-L1 checkpoint blockers to enhance the immune response to cancer, thereby providing a two-pronged approach to immunomodulation of the tumor microenvironment. Here, PDCD1 is linked to neoplasm.